SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: DRS
Document Type: DRS
Date Filed: 2025-08-05
Accession Number: 0001641172-25-022123
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000164117225022123/filename1.htm

Chunk 54 of 82
Word Count: 1429
Character Count: 8971

Document Content:

Shares of common stock Beneficially Owned Prior to Offering Shares of common stock Beneficially Owned After Offering Name and Address of Beneficial Owner (1) Number (7) (8) Percentage (2) Number Percentage Executive Officers, Directors and Director Nominees Steve Chartier 44,000 0.38 % [●] % Ori Ben-Yehuda 44,000 0.38 % David Richmond 3,881,771 (4) 33.724 % [●] % Mark Ravich 952,494 (6) 8.27 % [●] % All directors and executive officers as a group ([ ]individuals) % % or Greater Stockholders Michael Taglich 1,390,549 (5) 12.08 % [●] % Less than 1%. (1) Except as otherwise indicated, the business address of our directors and executive officers is 120 Forbes Blvd., Suite 125, Mansfield, MA (2) Based on 11,512,736 shares of common stock outstanding as of the date of this prospectus. (3) Based on [●] shares of common stock outstanding immediately after the offering assuming no exercise of the underwriters’ over-allotment option.

(4)	Includes
(a) 194,000 shares of common stock directly held by Mr. Richmond (including 25,665 shares of common stock from Second
RSU Grant 2024 and 18,335 shares of common stock from Second RSU Grant 2025), (b) 1,919,148 shares of common stock,
comprised of 148,400 Series A shares convertible into common stock and 1,770,748 Secured Convertible Notes held by
RBI BioVentrix LLC, (c) 461,223 shares of common stock comprised of 385,832 shares of common stock and 75,391 Series
A shares convertible into common stock held by RBI Opportunities Fund LLC, (d) 388,304 Secured Convertible Notes
held by RBI BioVentrix, LLC, (e) 355,595 shares of common stock comprised of 311,668 shares of common stock and 43,927
Series A shares convertible into common stock held by RBI BV Private Investment, (f) 277,590 common shares comprised of 226,025
shares of common stock and 51,565 Series A shares convertible into common stock held by RBI Private Investment III
LLC, (g) 255,740 shares, comprised of 215,077 shares of common stock and 40,663 Series A shares convertible into
common stock held by RBI Opportunities Fund II LLC, (h) 11,199 shares comprised of 8,300 shares of common stock
and 2,899 Series A shares convertible into common stock held by David Richmond & Stephanie Richmond, (i) 9,486 shares
comprised of 8,123 shares of common stock and 1,363 Series A shares convertible into common stock held by RBI Private
Investment I LLC, and (j) 9,485 shares, comprised of 8,123 shares of common stock and 1,362 Series A shares convertible
into common stock held by Richmond Brothers Inc. Mr. Richmond is the Manager and has voting and investment control of RBI BioVentrix
LLC, RBI Opportunities Fund LLC, RBI BioVentrix, LLC, RBI BV Private Investment, RBI Private Investment III LLC, RBI Opportunities
Fund II LLC, David Richmond & Stephanie Richmond, RBI Private Investment I LLC, and Richmond Brothers Inc, (collectively, the
“Richmond Entities”). Mr. Richmond disclaims any beneficial ownership of the securities held by the Richmond Entities,
other than to the extent of any pecuniary interest he may have therein, directly or indirectly.

(5)	Includes
(a) 381,952 shares, comprised of 119,902 shares of common stock and 262,050 Series A shares convertible into common
stock held directly by Mr. Taglich, (b) 103,654 shares of common stock held by Taglich Brothers Inc., (c) 84,408 shares
of common stock held by Michael N. Taglich & Claudia Taglich, (d) 177 shares of common stock held by Claudia Ruggiero
Taglich, (e) 3,179 shares of common stock held by Michael Taglich C/F Amanda Taglich UTMA NY, (f) 3,179 shares of common
stock held by Michael Taglich C/F Lucy Taglich UTMA NY, (g) 3,179 shares of common stock held by Michael Taglich
C/F Stella Taglich UTMA NY, (h) 130,142 shares of common stock held by Michael N. Taglich Keogh Account, (i) 3,179 shares
of common stock held by Michael Taglich TTEE Hope A Taglich Supplemental Needs Trust UAD 8/23/17, and (j) 677,500 Series A
shares convertible into common stock held by Bioventrix investors LLC. Mr. Taglich is the President of Taglich Brothers Inc.,
Michael N. Taglich Keogh Account, Michael Taglich TTEE Hope A Taglich Supplemental Needs Trust UAD 8/23/17, and Bioventrix investors
LLC and has voting and investment control over the shares held by Michael N. Taglich & Claudia Taglich, Claudia Ruggiero Taglich,
Michael Taglich C/F Amanda Taglich UTMA NY, Michael Taglich C/F Lucy Taglich UTMA NY, and Michael Taglich C/F Stella Taglich UTMA
NY (collectively, the “Taglich Entities”). Mr. Taglich disclaims any beneficial ownership of the securities held by the
Taglich Entities, other than to the extent of any pecuniary interest he may have therein, directly or indirectly.

(6)	Includes
(a) 165,000 common shares directly held by Mr. Ravich (including 57,750 common shares from Second RSU Grant 2024 and 41,250 common
shares from Second RSU Grant 2025), (b) 252,055 common shares comprised of 10,000 Series A and 242,055 Secured Convertible
Notes held by Mark Ravich Irrevocable Trust, (c) 199,754 common shares comprised of 79,880 Series A and 119,874 Secured
Convertible Notes held by Mark Ravich Revocable Trust, (d) 103,590 common shares comprised of 93,590 common shares and 10,000
Series A shares held by Mark Ravich TTEE Mark Ravich Irrevocable Trust UAD 11/05/18, (e) 87,938 common shares held by Mark H. Ravich
TTEE Revocable Trust of Mark H. Ravich UAD 10/08/19, (f) 64,693 common shares comprised of 5,000 Series A and 59,693
Secured Convertible Notes held by Norman and Sally Ravich Family Trust, (g) 40,261 common shares held by Mark Ravich TTEE
Cindy Libman Irrevocable Trust UAD 11/05/18, (h) 17,482 common shares held by Mark H. Ravich TTEE Norman & Sally Ravich Family
Trust UAD 12/24/92, (i) 8,123 common shares held by Alexander Coleman Ravich 1991 Irrevocable Trust, (j) 8,123 common shares held
by Alyssa Danielle Ravich 1991 Irrevocable Trust, and (k) 5,475 common shares held by Ilyne Ravich. Mr. Ravich is the Trustee and
has voting and investment control of Mark Ravich Irrevocable Trust, Revocable Trust of Mark Ravich, Mark Ravich TTEE Mark Ravich
Irrevocable Trust UAD 11/05/18, Mark H. Ravich TTEE Revocable Trust of Mark H. Ravich UAD 10/08/19, Norman and Sally Ravich Family
Trust, Mark Ravich TTEE Cindy Libman Irrevocable Trust UAD 11/05/18, Mark H. Ravich TTEE Norman & Sally Ravich Family Trust UAD
12/24/92, Alexander Coleman Ravich 1991 Irrevocable Trust, and Alyssa Danielle Ravich 1991 Irrevocable Trust (collectively, the “Ravich
Entities”). Mr. Ravich disclaims any beneficial ownership of the securities held by the Ravich Entities, other than to the
extent of any pecuniary interest he may have therein, directly or indirectly.

(7)	For
note conversions into shares assumes that interest accrues through May 31, 2025 on
the March 2024 through August 2024 Secured Convertible Note Financing and the October 8,
2024 through December 20, 2024 Series A-1 Secured Convertible Note Financing.

(8)	The
Secured Convertible Notes have a $10 per share conversion price. The share conversions assume
the initial public offering price is above $10 per share.

CERTAIN
RELATIONSHIPS AND RELATED PARTY TRANSACTIONS

During
the period from January 1, 2023 to the date of this prospectus, we have entered into or participated in the following transactions with
related persons:

On January 15, 2025,
Mr. Chartier, our Co-Chief Executive Officer and President, was granted 222,000 stock options at an exercise price of $1.00 per
share. The option shares vest 55,500 after one year and, thereafter, 4,625 of the option shares shall vest at the end of each full
month over thirty-six (36) consecutive months.

On January 1, 2025,
Mr. Richmond, our Co-Chief Executive Officer and Chief Financial Officer was granted 191,000 stock options at an exercise price of
$1.00 per share. The option shares vest 47,750 after one year and, thereafter, 3,979 of the option shares shall vest at the end of
each full month over thirty-six (36) consecutive months.

In March 2024, officers
and directors received 348,000 shares of restricted stock awards, 232,000 shares valued at $0.80 per share vested immediately.

In March 2024, Mr. Richmond, our Co-Chief Executive Officer and Chief Financial Officer
and entities controlled by him purchased $1,830,000 Series A Secured Convertible Notes from us.

In February 2024, Mr.
Taglich and Mr. Richmond and entities controlled by them purchased 650,000 Preferred Series A shares from other investors Mr. Taglich and Mr. Richmond subsequently sold 195,780 of these shares to us at cost to be used as incentive for certain purchasers of Series A Secured
Convertible Notes (the “Sweetener Shares”). We acquired an additional 30,120 Preferred Series A shares from Mr. Mark Ravich
for a total of 225,900 Sweetener Shares.

March 20, 2023, we entered into a Voting Agreement with holders of the Series A Preferred Stock. According to its terms, the Voting Agreement
will terminate upon the closing of this offering.